WO2008140251A2 - Inhibiteurs de la cyclooxygénase-2 - Google Patents
Inhibiteurs de la cyclooxygénase-2 Download PDFInfo
- Publication number
- WO2008140251A2 WO2008140251A2 PCT/KR2008/002677 KR2008002677W WO2008140251A2 WO 2008140251 A2 WO2008140251 A2 WO 2008140251A2 KR 2008002677 W KR2008002677 W KR 2008002677W WO 2008140251 A2 WO2008140251 A2 WO 2008140251A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- 5dione
- pyrrole
- pharmaceutically acceptable
- acceptable salt
- phenyl
- Prior art date
Links
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims abstract description 31
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims abstract description 17
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 206010061218 Inflammation Diseases 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical class O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims abstract description 11
- 208000035475 disorder Diseases 0.000 claims abstract description 10
- 230000004054 inflammatory process Effects 0.000 claims abstract description 10
- 208000002193 Pain Diseases 0.000 claims abstract description 8
- 206010003246 arthritis Diseases 0.000 claims abstract description 7
- 206010048768 Dermatosis Diseases 0.000 claims abstract description 5
- 206010037660 Pyrexia Diseases 0.000 claims abstract description 5
- 230000000172 allergic effect Effects 0.000 claims abstract description 5
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 5
- 230000001900 immune effect Effects 0.000 claims abstract description 5
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 5
- 208000017520 skin disease Diseases 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 58
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- IMHGOAWBSJVILI-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-4-phenylfuran-2,5-dione Chemical compound O=C1OC(=O)C(C=2C=C3OCOC3=CC=2)=C1C1=CC=CC=C1 IMHGOAWBSJVILI-UHFFFAOYSA-N 0.000 claims description 2
- LCBYKMOZFZMSHI-UHFFFAOYSA-N 4-(2,5-dioxo-4-phenylpyrrol-3-yl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)NC1=O LCBYKMOZFZMSHI-UHFFFAOYSA-N 0.000 claims description 2
- SGDZIHAQLUJVRO-UHFFFAOYSA-N [4-[4-(4-methylsulfonylphenyl)-2,5-dioxofuran-3-yl]phenyl] acetate Chemical compound C1=CC(OC(=O)C)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)C(=O)OC1=O SGDZIHAQLUJVRO-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- NRUQPBSJDZELAC-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-4-phenylpyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C=C3OCOC3=CC=2)=C1C1=CC=CC=C1 NRUQPBSJDZELAC-UHFFFAOYSA-N 0.000 claims 1
- AGSCBZRFFRZCGJ-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-4-phenylpyrrole-2,5-dione Chemical compound C1=C(O)C(O)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)NC1=O AGSCBZRFFRZCGJ-UHFFFAOYSA-N 0.000 claims 1
- HFMPFPQMCGYGCY-UHFFFAOYSA-N 3-phenyl-4-(3,4,5-trihydroxyphenyl)pyrrole-2,5-dione Chemical compound OC1=C(O)C(O)=CC(C=2C(NC(=O)C=2C=2C=CC=CC=2)=O)=C1 HFMPFPQMCGYGCY-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 31
- 239000011541 reaction mixture Substances 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 22
- 238000005160 1H NMR spectroscopy Methods 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- -1 methoxy, ethoxy, propanoxy Chemical group 0.000 description 10
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 10
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 8
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 6
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 150000003180 prostaglandins Chemical class 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229960003424 phenylacetic acid Drugs 0.000 description 5
- 239000003279 phenylacetic acid Substances 0.000 description 5
- FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical compound OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229940110331 bextra Drugs 0.000 description 4
- 229940047495 celebrex Drugs 0.000 description 4
- 229960000590 celecoxib Drugs 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 229960002004 valdecoxib Drugs 0.000 description 4
- 241001529936 Murinae Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 2
- WCTJRKVPYCQVQM-UHFFFAOYSA-N 2-(4-acetyloxyphenyl)acetic acid Chemical compound CC(=O)OC1=CC=C(CC(O)=O)C=C1 WCTJRKVPYCQVQM-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 229960002385 streptomycin sulfate Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- VTESCYNPUGSWKG-UHFFFAOYSA-N (4-tert-butylphenyl)hydrazine;hydrochloride Chemical compound [Cl-].CC(C)(C)C1=CC=C(N[NH3+])C=C1 VTESCYNPUGSWKG-UHFFFAOYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- ODVLMCWNGKLROU-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2OCOC2=C1 ODVLMCWNGKLROU-UHFFFAOYSA-N 0.000 description 1
- DDSJXCGGOXKGSJ-UHFFFAOYSA-N 2-(3,4,5-trimethoxyphenyl)acetic acid Chemical compound COC1=CC(CC(O)=O)=CC(OC)=C1OC DDSJXCGGOXKGSJ-UHFFFAOYSA-N 0.000 description 1
- FQSSPHAFXLRJBR-UHFFFAOYSA-N 2-(4-chlorosulfonylphenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(S(Cl)(=O)=O)C=C1 FQSSPHAFXLRJBR-UHFFFAOYSA-N 0.000 description 1
- CNTWKFSHBOORCI-UHFFFAOYSA-N 2-phenyl-2-sulfamoylacetamide Chemical compound NC(=O)C(S(N)(=O)=O)C1=CC=CC=C1 CNTWKFSHBOORCI-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- ONQJETBPCNSDIF-UHFFFAOYSA-N 3,4-bis[(4-hydroxyphenyl)methyl]oxolan-2-one Chemical compound C1=CC(O)=CC=C1CC1C(CC=2C=CC(O)=CC=2)C(=O)OC1 ONQJETBPCNSDIF-UHFFFAOYSA-N 0.000 description 1
- OUJCFCNZIUTYBH-UHFFFAOYSA-N 3,4-diphenylfuran-2,5-dione Chemical compound O=C1OC(=O)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OUJCFCNZIUTYBH-UHFFFAOYSA-N 0.000 description 1
- RQKNHGJPORHAPH-UHFFFAOYSA-N 3-(4-methylsulfonylphenyl)-4-phenylpyrrole-2,5-dione Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)NC1=O RQKNHGJPORHAPH-UHFFFAOYSA-N 0.000 description 1
- DGTUYXGVLCPASI-UHFFFAOYSA-N 3-phenyl-4-(3,4,5-trimethoxyphenyl)furan-2,5-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2C(OC(=O)C=2C=2C=CC=CC=2)=O)=C1 DGTUYXGVLCPASI-UHFFFAOYSA-N 0.000 description 1
- MROJXXOCABQVEF-UHFFFAOYSA-N Actarit Chemical compound CC(=O)NC1=CC=C(CC(O)=O)C=C1 MROJXXOCABQVEF-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012380 dealkylating agent Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical class Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- AALUTIYNYXEFNT-UHFFFAOYSA-N trimethylsilane hydroiodide Chemical compound C[SiH](C)C.I AALUTIYNYXEFNT-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to lH-pyrrole or furan-2,5dione derivatives and a pharmaceutical composition for inhibiting cyclooxygenase-2(COX-2), more specifically for treating or preventing inflammation, an allergic disorder, inflammatory dermatosis, an immunologic disorder, a neurodegenerative disorder, arthritis, pain or fever comprising the same.
- Cyclooxygenase- 1 is also called prostaglandin ⁇ jsynthase and expressed in most of tissues. Prostaglandin ⁇ jproduced by cyclooxygenase- 1 is involved in the synthesis and supply of arachidonic acid metabolites to regulate physiological processes such as protection of gastrointestinal cells, kidney function and platelet aggregation. Meanwhile, cy- clooxygenase-2 is also known as prostaglandin ⁇ synthase, which produces prostaglandin ⁇ to induce inflammation and pain. Cyclooxygenase-2 is expressed only
- Non-steroidal anti-inflammation drugs such as aspirin and ibuprofen exhibit their medicinal effects through inhibiting the activity of cyclooxygenases and suppressing the biosynthesis of prostaglandins.
- the non-steroidal anti-inflammatory drugs not only inhibit the activity of cyclooxygenase-2 to reduce inflammation but also inhibit the activity of cyclooxygenase- 1 to cause adverse effects such as renal toxicity and gastrointestinal ulceration. Therefore, there has been a need in the art for the development of an anti-inflammation drug selectively inhibiting cyclooxygenase-2 over cyclooxygenase- 1.
- Cyclooxygenase-2 inhibitors which have been commercialized until now include celecoxib (Celebrex) and valdecoxib (Bextra) developed by Pfizer, and rofecoxib (Vioxx) developed by Merck.
- Celecoxib (Celebrex) (a) can be used for the treatment of arthritis and severe pain
- rofecoxib (Vioxx) (b) can be used for the treatment of pain and inflammation
- valdecoxib (Bextra) c) can be extensively used for the treatment of rheumatism and arthritis.
- An object of the present invention is, therefore, to provide a compound of the following formula (I) or pharmaceutically acceptable salt thereof having excellent cyclooxygenase-2 inhibitory effect.
- Another object of the present invention is to provide a pharmaceutical composition for inhibiting cyclooxygenase-2 comprising the compound of the following formula (I) or pharmaceutically acceptable salt thereof as an active ingredient.
- One aspect of the present invention relates to a compound of the following formula (I) or pharmaceutically acceptable salt thereof having excellent cyclooxygenase-2 inhibitory effect.
- R , R and R are each independently hydrogen, hydroxy, C -C lower alkoxy, R
- R is C -C lower alkyl
- X is O or NH.
- the heterocycle is, preferably, dioxolane or dioxane; and R is, most preferably, methyl.
- C -C lower alkoxy as used herein means a straight or branched alkoxy group having 1 to 5 carbon atoms, which includes methoxy, ethoxy, propanoxy, etc. but is not limited thereto.
- Heterocycle as used herein means a 4 to 74nembered ring having 1 to 3 heteroatom(s) selected from the group consisting of oxygen, sulfur and nitrogen, which includes dioxolane, dioxane, etc. but is not limited thereto.
- C -C lower alkyl as used herein means a straight or branched hydrocarbon having 1 to 5 carbon atoms, which includes methyl, ethyl, propyl, butyl, pentyl, hexyl, etc. but is not limited thereto.
- the most preferable compound among the compounds of the present invention is selected from the following group.
- a furan-2,5dione derivative(3) can be prepared by reacting phenylgly oxalic acid (1) and phenylacetic acid (2) in acetic anhydride.
- the acetic anhydride is used as a reactant as well as solvent.
- the reaction temperature is preferably from room temperature to 13O 0 C, most preferably about 100 0 C.
- the reaction time is preferably 2-10 hours, most preferably about 3 hours.
- an acid catalyst can be used, which includes titanium chloride(TiCl ), BF (OEt) , thionyl chloride (SOCl ), etc. but is not limited
- a lH-pyrrole-2,5dione derivative(4) can be prepared by treating a furan-2,5dione derivative (3) with methanol, dimethyl- formamide (DMF) and hexamethyldisilazane (HMDS).
- the reaction temperature is most preferably room temperature, and the reaction time is preferably 10-36 hours, most preferably 12 hours.
- ammonia gas can be used in a solvent such as acetonitrile and lower alcohol including methanol.
- a lH-pyrrole-2,5dione derivative(5) wherein R , R and/or R are hydroxy can be prepared by dealkylating a lH-pyrrole-2,5dione derivative(4) wherein R , R and/or R are alkoxy or taken together with the carbon atoms to which they are attached form dioxolane or dioxane.
- the dealkylating agent includes boron tribromide (BBr ), trimethylsilane iodide (TMSI), aluminium chloride (AlCl ), etc. but is not limited thereto.
- a lH-pyrrole-2,5dione derivative (4) according to the present invention can be prepared by coverting phenylacetic acid (2) to acyl chloride, and then treating the acyl chloride with ammonia water to give pheny- lacetamide (6), followed by the condensation of the phenylacetamide (6) with an ester compound (7).
- Another aspect of the present invention relates to a pharmaceutical composition for inhibiting cyclooxygenase-2 comprising the compound of the above formula (I) or pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.
- the pharmaceutical composition of the present invention can be used for treating or preventing inflammation, an allergic disorder, inflammatory dermatosis, an immunologic disorder, a neurodegenerative disorder, arthritis, pain or fever.
- the pharmaceutical composition according to the present invention can be administered orally, e.g., ingestion or inhalation; or parenterally, e.g., injection, deposition, implantation or suppositories.
- the injection can be, for example, intravenous, intradermal, subcutaneous, intramuscular or intraperitoneal.
- the pharmaceutical composition of the present invention may be formulated as tablets, capsules, granules, fine subtilae, powders, sublingual tablets, suppositories, ointments, injection solutions, emulsions, suspensions, syrups, aerosols, etc.
- composition of the present invention can be prepared in a manner well known in the art using a pharmaceutically acceptable carrier(s) which are usually used for each form.
- pharmaceutically acceptable carriers include excipient, filler, expander, binder, disintegrator, lubricant, preservative, antioxidant, isotonic agent, buffer, coating agent, sweetening agent, dissolvent, base, dispersing agent, wetting agent, suspending agent, stabilizer, colorant, aromatic, etc.
- the pharmaceutical composition of the present invention contains 0.01 to 100 wt% of the compound according to the present invention or pharmaceutically acceptable salt thereof depending on the form thereof.
- the specific dosage of the present pharmaceutical composition can be varied with species of mammals including a human-being, route of administration, body weight, gender, age, severity of disease, judgment of doctor, etc. It is preferable that 0.01 to 50 mg of the active ingredient is administered per kg of body weight a day for oral use, while 0.01 to 10 mg of the active ingredient is administered per kg of body weight a day for parenteral use.
- the total daily dosage can be administered once or over several times depending on the severity of disease, judgment of doctor, etc.
- the compounds of the present invention have excellent cyclooxygenase-2 inhibitory activity and low cytotoxicity. Therefore, the compounds of the present invention can be used for preparing pharmaceutical compositions for treating or preventing inflammation, an allergic disorder, inflammatory dermatosis, an immunologic disorder, a neurodegenerative disorder, arthritis, pain or fever. Best Mode for Carrying Out the Invention
- the resulting solid was filtered and the filtrate was saturated with a saline solution and extracted with ethyl acetate three times.
- the organic phase was dried with anhydrous magnesium sulfate(MgSO ) and distilled under reduced pressure to give a solid product.
- the solid product combined with the previously obtained solid was re- crystallized with acetone to give the target compound as a white solid(Q9 g, 33 %).
- Example 11 Preparation of (4-thiomethoxyphenyl)oxoacetic acid [114] To the compound(4 g, 17.835 mmol) obtained in Example 5 was dropped 2N NaOH(8.9 ml) at room temperature, and the reaction mixture was stirred at room temperature for 3 hours. After the reaction was completed, the reaction mixture was acidified with concentrated HCl to pH 2 and extracted with CH Cl three times. The
- Example 15 Preparation of 3.4-diphenyl-l H -pyrrole-2.5dione (MCR-SOOD [134] 3,4-diphenylfuran-2,5dione was used according to the same procedure as Example
- Example 16 Preparation of 3-(3.4.5-trimethoxyphenyl s )-4-phenyl-l H - pyrrole-2.5dione fMCR-SX) ⁇ [139] 3-(3,4,5-trimethoxyphenyl)-4-phenylfuran-2,5dione obtained in Example 13 was used according to the same procedure as Example 14 to give the target compound(97
- reaction mixture (0.179 g, 0716 mmol) at -78 °C, and the reaction mixture was left to room temperature and stirred for 12 hours. After the reaction was completed, the reaction mixture was neutralized with a saturated NaHCO aqueous solution and extracted with ethyl acetate. The organic phase was washed with a saturated saline solution, dried with anhydrous magnesium sulfate(MgSO ) and distilled under reduced pressure to give the
- Example 18 Preparation of 3-(3A5-trihvdroxyphenyl)-4-phenyl-l H - pyrrole-2.5dione (MCR- 3009 s ) [149] 3-(3,4,5-trimethoxyphenyl)-4-phenyl-l H-pyrrole-2,5dione obtained in Example 16 was used according to the same procedure as Example 17 to give the target compound(88 %). [150] 1 H NMR (430 MHz, DMSO ⁇ i ) ⁇ 11.02 (IH, s, -NH), 9.00 (2H, s, OH), 8.61 (IH, s,
- cell viability was measured according to a 3-(4,5dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay.
- Raw264.7 cells (murine macrophage cell line), which were obtained from Korean Cell Line Bank(KCLB), were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), penicillin(100 units/mL) and streptomycin sulfate(10Q7g/mL) at 37 0 C in a humidified atmosphere with 5% CO .
- DMEM Dulbecco's modified Eagle's medium
- FBS fetal bovine serum
- penicillin(100 units/mL) penicillin(100 units/mL)
- streptomycin sulfate 10Q7g/mL
- Lipopolysaccharide(LPS) was added at l ⁇ g/mL and incubated for 24 hours(or appropriate time). The obtained supernatant was diluted five fold. 150 ⁇ L of analysis buffer was added to non specific binding(NSB) wells and lOO ⁇ L of analysis buffer was added to zero standard(BO) wells. lOO ⁇ L of standard samples were added to the other wells. 50 ⁇ L of PGE conjugates were added (except for NSB). Then, 50 ⁇ L of PGE antibody solution was added and shaken for 2 hours. Each well was subject to suction and washed with washing buffer five times.
- EIA Enzyme ImmunoAssay
- PG screening antiserum was added in 50 ⁇ L aliquots except for TA, NSB and BIk, and left at room temperature for 18 hours. Each well was subject to suction and washed with washing buffer 5 times. Ellman's reagent was added in 200 ⁇ L aliquots and tracer was added in 5 ⁇ L aliquots to only TA wells. The plates were shaken for 60-90 minutes with shielding the light and the absorbance was measured at 4)5 nm. The inhibition of COX-2 activity was evaluated using the measured absorbance and standard curve, and the concentration to inhibit by 50% (IC
- Raw264.7 cells (murine macrophage cell line) were cultured in Dulbecco's modified Eagle's medium(DMEM) containing 10% fetal bovine serum(FBS), penicillin(100 units/mL) and streptomycin sulfate(100 //g/mL) at 37 0 C in a humidified atmosphere with 5% CO .
- the cells were collected by centrifugation and scraper, and added in 1x10 cells/well to 96- well plates having lOO ⁇ L of Roswell Park Memorial Institute(RPM) 164) medium containing 10% FBS.
- 50 50 means the concentration to exhibit 50% reduction in the number of cells compared to the group which was not treated with compounds. The results are summarized in Table 2, where the values were obtained from three independent experiments.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention porte sur des dérivées du IH-pyrrole ou du furan-2,5dione et sur une composition pharmaceutique inhibitrice de la cyclooxygénase-2 (COX-2), et plus spécifiquement sur une telle composition traitant ou prévenant l'inflammation, les troubles allergiques, la dermatose inflammatoire, les troubles immunologiques, les troubles neurodégénératifs, l'arthrite, la douleur ou la fièvre.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2007-0046489 | 2007-05-14 | ||
KR20070046489 | 2007-05-14 | ||
KR10-2008-0014364 | 2008-02-18 | ||
KR1020080014364A KR100989141B1 (ko) | 2007-05-14 | 2008-02-18 | 시클로옥시게나제-2 저해제 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008140251A2 true WO2008140251A2 (fr) | 2008-11-20 |
WO2008140251A3 WO2008140251A3 (fr) | 2009-01-15 |
Family
ID=40002753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2008/002677 WO2008140251A2 (fr) | 2007-05-14 | 2008-05-14 | Inhibiteurs de la cyclooxygénase-2 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008140251A2 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101538256A (zh) * | 2009-04-28 | 2009-09-23 | 沈阳药科大学 | 3,4-二芳基呋喃-2,5-二酮类衍生物与3,4-二芳基-1h-吡咯-2,5-二酮类衍生物及其用途 |
WO2010069150A1 (fr) * | 2008-12-18 | 2010-06-24 | Mao Jinlong | Derives d'acide acrylique de para-hydroxybenzene et utilisations associees |
JP2013014534A (ja) * | 2011-07-04 | 2013-01-24 | Daicel Corp | ベンゾイルギ酸化合物、及びその製造方法 |
CN103804108A (zh) * | 2012-11-15 | 2014-05-21 | 沈阳药科大学 | 一种制备伯胺的方法 |
CN103951594A (zh) * | 2009-12-18 | 2014-07-30 | 毛近隆 | 对羟基苯丙烯酸衍生物及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993016674A1 (fr) * | 1992-02-11 | 1993-09-02 | Smithkline Beecham Corporation | INHIBITEURS DE LA CoA-IT ET DU PAF |
JPH10507765A (ja) * | 1994-10-27 | 1998-07-28 | メルク フロスト カナダ インコーポレーテツド | シクロオキシゲナーゼ−2阻害剤として有用なスチルベン誘導体 |
DE19711428A1 (de) * | 1997-03-19 | 1998-09-24 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE10155076A1 (de) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen |
-
2008
- 2008-05-14 WO PCT/KR2008/002677 patent/WO2008140251A2/fr active Application Filing
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010069150A1 (fr) * | 2008-12-18 | 2010-06-24 | Mao Jinlong | Derives d'acide acrylique de para-hydroxybenzene et utilisations associees |
CN101910144A (zh) * | 2008-12-18 | 2010-12-08 | 毛近隆 | 对羟基苯丙烯酸衍生物及其应用 |
CN101910144B (zh) * | 2008-12-18 | 2014-04-23 | 毛近隆 | 对羟基苯丙烯酸衍生物及其应用 |
CN101538256A (zh) * | 2009-04-28 | 2009-09-23 | 沈阳药科大学 | 3,4-二芳基呋喃-2,5-二酮类衍生物与3,4-二芳基-1h-吡咯-2,5-二酮类衍生物及其用途 |
CN101538256B (zh) * | 2009-04-28 | 2014-05-21 | 沈阳药科大学 | 3,4-二芳基呋喃-2,5-二酮类衍生物与3,4-二芳基-1h-吡咯-2,5-二酮类衍生物及其用途 |
CN103951594A (zh) * | 2009-12-18 | 2014-07-30 | 毛近隆 | 对羟基苯丙烯酸衍生物及其应用 |
JP2013014534A (ja) * | 2011-07-04 | 2013-01-24 | Daicel Corp | ベンゾイルギ酸化合物、及びその製造方法 |
CN103804108A (zh) * | 2012-11-15 | 2014-05-21 | 沈阳药科大学 | 一种制备伯胺的方法 |
CN103804108B (zh) * | 2012-11-15 | 2016-08-03 | 沈阳药科大学 | 一种制备伯胺的方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2008140251A3 (fr) | 2009-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2686306B1 (fr) | Dérivés de benzo [b][1, 4]oxazine en tant que modulateurs du récepteur sensible au calcium | |
EP1786773B1 (fr) | Derives d'isoindolin-1-one | |
RU2453536C2 (ru) | Ингибиторы гистондезацетилазы | |
Ghannay et al. | Novel enantiopure isoxazolidine and C-alkyl imine oxide derivatives as potential hypoglycemic agents: Design, synthesis, dual inhibitors of α-amylase and α-glucosidase, ADMET and molecular docking study | |
JP2003501464A (ja) | シクロオキシゲナーゼ−2の阻害剤としての1−(4−スルファミルアリール)−3−置換−5−アリール−2−ピラゾリン | |
CN106831489B (zh) | 苯环丙胺酰腙类化合物、制备方法及其应用 | |
JP2007509842A (ja) | 心血管障害の処置のためにApoA1の発現を誘導するための、一酸化窒素部分を含む化合物 | |
Ren et al. | Design and biological evaluation of novel hybrids of 1, 5-diarylpyrazole and Chrysin for selective COX-2 inhibition | |
EA016345B1 (ru) | Новые сульфонилпирролы в качестве ингибиторов гдац (гистондезацетилазы) | |
Renard et al. | N-(3-Arylaminopyridin-4-yl) alkanesulfonamides as pyridine analogs of nimesulide: Cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism | |
WO2008140251A2 (fr) | Inhibiteurs de la cyclooxygénase-2 | |
AU2014213396A1 (en) | Azole benzene derivative | |
Çapan et al. | Design, synthesis, molecular docking and biological evaluation of new carbazole derivatives as anticancer, and antioxidant agents | |
Tzankova et al. | Synthesis, in vitro safety and antioxidant activity of new pyrrole hydrazones | |
Bhat et al. | Novel sulindac derivatives: Synthesis, characterisation, evaluation of antioxidant, analgesic, anti-inflammatory, ulcerogenic and COX-2 inhibition activity | |
WO2008142550A9 (fr) | Dérivés spirocycliques | |
Hernández‐Vázquez et al. | Cytotoxic Activity and Structure–Activity Relationship of Triazole‐Containing Bis (Aryl Ether) Macrocycles | |
Moreau et al. | Design, synthesis, and biological evaluation of (E)-3-(4-methanesulfonylphenyl)-2-(aryl) acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases | |
Koç et al. | Synthesis of some novel hydrazide-hydrazones derived from etodolac as potential anti-prostate cancer agents | |
EP3145935A1 (fr) | Composés pharmaceutiquement actifs à titre d'inhibiteurs de lipases dag | |
Ferazoddin et al. | New quinoxaline‐piperazine‐oxazole conjugates: Synthesis, in vitro anticancer, in silico ADMET, and molecular docking studies | |
WO2019178480A1 (fr) | Inhibiteurs du facteur inhibiteur de migration des macrophages contenant du pyrazole | |
CA2787860C (fr) | 2-imidazolidones substitues et analogues et leur utilisation contre le cancer | |
Zhao et al. | Lead optimization of selective tubulin inhibitors as anti-trypanosomal agents | |
Cesarini et al. | Parallel one-pot synthesis and structure–activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08753473 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08753473 Country of ref document: EP Kind code of ref document: A2 |